FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...
Stay updated with breaking news from Robert Barrow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...
NEW YORK, Jan. 25, 2022 /PRNewswire/ -- Mind Medicine Inc. , , a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based... | January 25, 2022
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Jan. 19, 2022 /PRNewswire/ -- After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received
/PRNewswire/ -- After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical...
This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh&n...